Compare Neurocrine Biosciences Inc (NBIX) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $141.13 (market cap $14.36B), while Virgin Galactic Holdings, Inc. trades at $2.88 (market cap $445.69M). The key difference: Neurocrine Biosciences Inc is far larger — about 32.2× Virgin Galactic Holdings, Inc.'s market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| NBIX | SPCE | |
|---|---|---|
Market Cap | $14.36B | $445.69M |
Volume | 1,237,180 | 5,128,850 |
Sector | Health | Industrials |
52-Week High | $185.50 | $7.52 |
52-Week Low | $123.10 | $2.17 |
Typical Hold Time | 23 Days | 69 Days |
Enterprise Value | $14.37B | $409.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Virgin Galactic (SPCE) trades at $3.01, down 1.95% on the day, reflecting ongoing investor skepticism despite recent earnings beats. The company continues to burn cash with negative operating cash flow of $240.14 million in 2025 and deeply negative profit margins. Technical indicators show a bearish trend with the stock trading near key support levels. Recent news highlights management's guidance for positive cash flow by 2027 but also a delay in commercial Delta flights to February 2027.
The outlook remains highly speculative with significant execution risk. While strong ticket demand provides a potential catalyst, the path to profitability is long and dependent on successful commercial spaceflight operations. Investors face substantial dilution risk and high volatility in this pre-revenue growth phase. The stock represents a high-risk, high-reward opportunity suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
